Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|May 22, 2017
Alternative Approaches to Prior Authorization in Specialty Pharmacy
Author(s)Lauren Santye, Assistant Editor
Sheila Arquette, RPh, director of Pharmacy Services at Independent Health, discusses how specialty stakeholders can improve clinical and financial alignment.
Advertisement
Sheila Arquette, RPh, director of Pharmacy Services at Independent Health, discusses how specialty stakeholders can improve clinical and financial alignment.
Advertisement
Related to this article
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
Dapagliflozin in Heart Failure: Congestion Isn't the Gatekeeper
3
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
4
FDA Approves Levacetylleucine to Treat Ataxia in Adult, Pediatric Patients With A-T
5